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Introduction
An estimated 5.6 million South Africans are living with human 
immunodeficiency virus (HIV infection). With a national, prevalence of 
29.5%  and over 460 000 HIV-infected children in South Africa,1 there is 
an urgent need to address the health of women and children who remain 
at the centre of the pandemic in terms of vulnerability, transmission and 
potential for intervention. 
The mother is usually the primary or sole caregiver in Africa, and it is 
well documented that maternal well-being plays a critical role in the 
physical and mental health of children.2,3 This is supported by studies 
in Uganda which suggest that maternal HIV infection increases the 
mortality risk of their children.4,5 Hence the care of infants and children 
should incorporate the whole family unit, with particular emphasis on 
the mother. Apart from the impact of an estimated 1.2 million maternal 
acquired immune deficiency syndrome (AIDS) orphans in South Africa,6 
direct and indirect consequences of maternal ill health need to be 
considered. Importantly, the caregiver plays a critical role in achieving 
success with the child’s HIV care by preventing virological failure and 
resistance through adherence to lifelong medication.
Early and accurate identification of mothers in need of antiretroviral 
therapy (ART) is one of the cornerstones of preserving maternal 
health. The CD4 test remains the gold standard surrogate marker of 
the immunological health of HIV-positive patients prior to and while on 
ART, and guides decisions on when to initiate and adjust treatment.7-9 
Recently, point-of care (POC) CD4 analysers, such as the Alere Pima™ 
Analyser (Pima™), have been developed, with onsite finger-prick CD4 
testing which produces rapid results within 20 minutes. Hence, POC 
testing may provide a valuable supplementary option to determine CD4, 
especially in rural settings where delays in CD4 count turnaround times 
or lack of availability of the test, result in failure to initiate ART and/or 
patient loss to follow-up.
We evaluated the paediatric HIV care visit as an opportunity to identify 
maternal ART eligibility in cases where mothers had missed their routine 
CD4 screening. To prevent further loss to follow-up, we used the Pima™ 
to obtain the result immediately, and compared and controlled this with 
a traditional laboratory CD4 test.
Method
This cross-sectional descriptive prospective study was conducted 
by researchers at the HOPE Cape Town Association and Trust, a non-
governmental organisation (NGO) within Tygerberg Children’s Hospital. 
Study participants were known to be the HIV-positive mothers of 
children who were either attending appointments at Tygerberg Hospital, 
or who were admitted to the Infectious Diseases Ward. The caretaker 
had to be an HIV-positive biological mother to be included in the study. 
Exclusion criteria were mothers who were already on ART, those already 
known to be eligible for ART, and those with a CD4 count of more than 
500/μl  within the preceding six months. The Western Cape Department 
of Health (DOH) ART guidelines, based on the South African national DOH 
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ART guidelines, were used to define the eligibility criteria for starting 
ART.10 These criteria included a CD4 threshold of 350 cells/μl or less, the 
presence of tuberculosis, or a World Health Organization (WHO) clinical 
stage IV illness, regardless of CD4.
Participants were recruited by the HOPE Cape Town Association and 
Trust medical doctor from November 2011 to May 2012. A convenience 
sample of 52 patients was chosen. Each participant gave written 
consent to undergo a basic medical examination to clinically stage the 
HIV progression, according to the WHO clinical staging of HIV/AIDS for 
adults and adolescents,11 and to have blood taken. Two blood samples 
were taken: a finger-prick capillary sample for the POC CD4, and a 
venous sample for the laboratory panleukogated (PLG) CD4, the CD4 
reference standard for the study.12
The Pima™ was used to determine the finger-prick results. Prior to 
testing, three NGO staff members involved in operating the Pima™ were 
trained in finger-prick methodology and instrument use by the supplier, 
as prescribed by the manufacturer. Daily quality control assessments 
were performed on the Pima™ with the manufacturer-supplied reusable 
bead-filled cartridges (high and low controls). Finger-prick samples were 
obtained with Sarstedt lancets with a 1.5 mm blade. Self-contained 
disposable Pima™ test cartridges, with an integrated capillary to capture 
5 μl of sample were used. The participants’ CD4 results from the Pima™ 
were determined and interpreted within 20 minutes.  
Venous blood was collected simultaneously by phlebotomy in a 4 ml 
ethylenediaminetetraacetic acid (EDTA) tube for the routine method 
of care (PLG) laboratory CD4 determination, and analysed using 
standardised protocols on a Beckman Coulter Flow Cytometer 500 
MPL® (FC 500 MPL®) at the National Health Laboratory Services (NHLS), 
Tygerberg. Daily internal quality controls and bimonthly external quality 
control samples from the CD4 reference centre are run for this method. 
The results of external quality assurance results have to be within two 
standard deviations (SDs). The Tygerberg NHLS immunology laboratory 
is accredited with South African national accreditation systems. The 
laboratory staff was blinded to the Pima™ CD4 results. The FC 500 MPL® 
CD4 results were received via e-mail by the NGO doctor the following 
day, and then faxed to the participants’ respective clinic. In addition, 
each participant received a letter addressed to her clinic, containing her 
WHO clinical staging and Pima™ CD4 result. This letter explained that 
the Pima™ results were not yet validated, and treatment decisions and 
direct comparisons to previous CD4 results should be based solely on 
the confirmatory laboratory CD4 result. This aimed to prevent the use of 
POC results to determine ART was necessary.
Clinical data were recorded in a secure Microsoft® Excel® database 
and Statistica® version 10 was used to analyse and display the data. 
The median values, together with the interquartile range (IQR), were 
calculated for the Pima™ and FC 500 MPL® CD4 results. To determine 
the limits of agreement between data obtained from the Pima™ CD4 
analyser and those obtained from the FC 500 MPL® laboratory method, 
the Bland-Altman statistical bias analysis was performed by graphically 
plotting the difference between each data pair against the average of the 
pair methods. The average absolute difference between the two methods 
(the bias) and the limits of agreement (equivalent to the mean difference 
± 1.96 SD) was then calculated.13 Further supporting statistical analysis 
was performed using the percentage similarity (% SIM) model analysis, 
whereby the average between a new method and the gold standard is 
represented as a percentage of the gold standard. The representation of 
the percentage similarity values in a histogram format draws attention to 
the accuracy and precision of the compared method to a gold standard. 
The calculation of a coefficient of variation further defines agreement 
between methods.14
The Committee for Health Research Ethics at Stellenbosch University 
approved the study (N11/09/269) and the South African Medical 
Research Council and Declaration of Helsinki guidelines on the conduct 
of clinical research were followed. 
Results 
Fifty-two patients were recruited to the study. The results of two patients 
had to be excluded from the direct comparison analysis owing to a “no 
read/invalid” CD4 reading on the Pima™ analyser in one case, and the 
inability to perform analysis using the FC 500 MPL® because of a clotted 
venous blood sample in the other. 
According to the Pima™ CD4 analyser results, 37% (19 of 51) of mothers 
were identified with a CD4 count of 350 cells/μl or less, meeting the 
eligibility criteria for the initiation of ART. This compared to 35% (18 of 
51) of mothers similarly identified by the FC 500 MPL® CD4 method. 
Five sample results were discrepant, with three out of 19 POC samples 
giving false positive results for ART eligibility, and two of the 18 FC 500 
MPL® CD4 samples being false negatives. Furthermore, an additional 
4% (two of 51) of mothers were eligible for ART based on their clinical 
assessment alone [WHO stage III (pulmonary tuberculosis)], despite 
having CD4 > 350 cells/μl according to the FC 500 MPL® results. It is 
noteworthy that 100% of mothers who were eligible for ART (based on 
their laboratory CD4 counts) were WHO clinical stage I or II.
The median Pima™ CD4 result (n = 51) was 420 cells/μl (IQR 310-631), 
while the corresponding median FC 500 MPL® CD4 result (n = 51) was 
394 cells/μl (IQR 264-535). The median difference was 11.5 cells/μl 
(IQR −29 to + 68).
As shown in Table I, the sensitivity of the Pima™ in detecting CD4  ≤ 350 
cells/μl (as defined by the FC 500 MPL®  CD4 result) was 89% [95% 
confidence interval (CI): 74-100], the specificity 91% (95% CI: 81-100), 
and the positive and negative predictive values 84% (95% CI: 68-100) 
and 94% (95% CI: 85-100).  
Table I: Sensitivity and specificity based on CD4 threshold of 350 cells/μl
FC 500 MPL® CD4
≤ 350 cells > 350 cells Total
Pima™ CD4
≤ 350 cells 16 (89%) 3 (9%) 19
> 350 cells 2 (11%) 29 (91%) 31
Total 18 32 50
Beckman Coulter Flow Cytometer 500 MPL®, FC 500 MPL®: Pima™: Alere Pima™ Analyser
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Receiver operating characteristic curve analysis was also performed, 
whereby potential values from the sample group were considered 
to be potential values that would best relate to a PLG cut-off of ≤ 350 
cells/μl. The Pima™ value with the best combination of sensitivity and 
specificity in predicting a PLG cut-off of ≤ 350 cells/μl (ART eligibility) 
was fortuitously found to be exactly 350 cells/μl. Figure 1, showing an 
area under the curve of 0.98, shows how the results match those in 
Table I.
The mean bias of the Pima™ CD4 analyser was +23.86 cells/μl (95% 
CI: −3.6  to +51.4) relative to the FC 500 MPL®, with 95% limits of 
agreement from −166.1 cells/μl to +213.8 cells/μl (Figure 2). Additional 
% SIM analysis (Figure 2) showed similar results (n = 50, mean % SIM 
104.8% ± SD = 16.1%). % SIM coefficient of variation (CV) showing 
precision of Pima™ to FC 500 MPL® was 15.39% (Figure 3).
Discussion
The findings in this study document the value of the routine paediatric 
HIV visit as an intervention opportunity to assess maternal ART 
eligibility. More than one third of mothers who had previously missed 
their routine CD4 screening opportunities were identified as requiring 
ART. This represents a significant number of mothers who would have 
been lost within the healthcare system. At the paediatric visit, the focus 
of the healthcare worker and the mother is on the child’s health, with 
the mother’s own health often being overlooked until symptoms of 
illness occur.  A study that was conducted in KwaZulu-Natal showed 
that children of women who were HIV-infected and not initiated on ART 
were four times more likely to die than children of uninfected mothers.15 
Expanding the focus of the paediatric visit to include the preventative 
health care of the child’s mother, with an emphasis on ART eligibility, 
ensures that an important gap in HIV care is addressed. Moreover, 
the Joint United Nations Programme on HIV/AIDS has recognised the 
importance of integrating maternal HIV interventions into child health 
services.16
Our results show that 100% of the mothers who were eligible for ART, 
based on their laboratory CD4 counts, were clinical stage I or II. These 
results concur with those of other studies which demonstrated that 
clinical staging alone was not sufficient or reliable in ascertaining ART 
eligibility, and that it frequently correlated poorly with immunological 
markers.7-9 However, clinical assessment and staging should not be 
completely discounted. In our study, two mothers whose laboratory CD4 
counts were above the initiation threshold of 350 cells/ul (508 cells/
µl and 452 cells/µl) were still in need of ART based on their clinical 
staging [WHO clinical stage III (tuberculosis]). Interestingly, in both 
cases, the Pima™ CD4 analyser reported CD4 results lower than the 
laboratory results (414 cells/ul and 350 cells/µl, respectively), thereby 
classifying one of these patients as requiring ART. This overall finding re-
emphasises the importance of a routine clinical assessment and staging, 
as an adjunct to CD4 count staging.
Figure 1: The results of the receiver operating curve analysis, showing the 
optimal Pima™ value to be 350 cells/μl
% SIM CV: percentage similarity coefficient of variation
 Mean difference: 23.86
 Mean - 1.96 standard deviation = -166.09
 Mean + 1.96 standard deviation = 213.82
Figure 2: Bland-Altman plots were analysed by plotting the difference 
between the absolute CD4 T-lymphocyte values generated using the Pima™ 
CD4 analyser and those from the FC 500 MPL® CD4 system, against the 
mean absolute values of the paired systems (n = 50) 
Figure 3: Percentage similarity plot of absolute CD4 T-lymphocyte count de-
riving from the Pima™ CD4 analyser and from the FC 500 MPL
® CD4 system
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POC diagnostics present a further opportunity, particularly in resource-
limited settings, to provide early access to screening and testing, and 
may have the potential of improving ART initiation rates, reducing 
the number of clinic visits and preventing possible loss to follow-up. 
However, the uptake of such technology has been slow. This is because 
of a current lack of policy in the public health sector for POC CD4 testing, 
combined with limited guidance on optimal implementation strategies 
and the challenges of ensuring test quality, as testing is decentralised 
to more rural settings. The African Society for Laboratory Medicine is 
in the process of addressing and overcoming these difficulties, and it 
is likely that in the near future, POC systems will be incorporated, in 
some form, into our healthcare systems.17 In the South African context, 
difficulties with screening, testing, initiating ART and retaining patients 
in care are multifactorial, and it is important to acknowledge that POC 
technologies alone may have an important, but limited, role in providing 
solutions to these. 
Larger studies that were conducted in Thailand, Senegal and South 
Africa, where the primary focus was on Pima™ CD4 analyser validation, 
showed the Pima™ system to be a simple and reliable method of 
screening HIV-positive adults in resource limited-settings.18-20 Unlike 
conditions in these studies whereby different variables were controlled, 
such as using EDTA venous, instead of finger-prick, blood samples, 
and ensuring use of the same machines and operators, our study was 
designed to reflect a realistic “add-on to routine care” situation in which 
the Pima™ is likely to be used in South Africa. It is important to note 
that other studies in this realistic operation framework have shown that 
formal practical training on capillary blood sampling and rigid adherence 
to operating protocol is imperative in ensuring the accuracy of the Pima™ 
CD4 results.
20,21 This is a critical step, required to ensure the success 
of POC services, particularly in rural settings where skills, support 
and monitoring may be limited. It would be necessary to identify and 
nominate specific personnel in clinics to undergo specialised, preferably 
onsite, capillary blood sampling training. This would need to be sustained 
with ongoing training, and reinforced with strict monitoring protocols. 
However, it is encouraging to see that under well supported conditions, 
as a screening test for ART eligibility, the Pima™ has repeatedly shown 
good sensitivity and predictive values in studies in Uganda, South Africa 
and Zimbabwe.22-24  
Validation of the Pima™ CD4 analyser was a secondary objective in our 
study, and it showed promising results, with a reasonable sensitivity, 
specificity and a clinically acceptable mean bias of +23.86 cells/μl, 
compared to the gold standard. Even though the limits of agreement 
seemed to be relatively wide (a total of 379 cells/μl), they were able 
to contend reasonably well with similar local field studies, where 
limits of agreement ranged from an acceptable total of 272 cells/μl to 
an unacceptable total of 635 cells/μl.21 Unlike other studies that have 
shown increasing bias with increasing CD4 count results, our study did 
not reveal a noticeable change in Pima™ CD4 analyser accuracy at a 
higher or lower CD4 count range.18,20,25 This may be problematic in lower, 
clinically relevant CD4 ranges (300-400 cells/μl) where a variation  in 
results may result in the misclassification of ART eligibility. This may 
need to be considered when making recommendations.
Further analysis of Pima™ precision showed a % SIM CV of 15.39%, 
which fell within acceptable levels in similar local studies (varying from 
17.6-28.8% CV), but neither attained optimal precision levels (10-11.3% 
CV).21 Despite this relative imprecision when compared to laboratory 
based testing, it is important to highlight that with the sensitivity of 89% 
and specificity of 91% obtained in our study, very few patients were 
missed at the 350 cells/ul-threshold for ART initiation. Thus, overall, 
Pima™ fulfilled an essential role in making patients aware of their ART 
eligibility status at the time of their consultation visit, with minimal delay.
Notably, the high negative predictive value of 94% highlights the potential 
usefulness of the Pima™ CD4 as a “rule out” test. Based on this, it could 
be recommended that if the Pima™ returned a result of greater than 350 
cells/μl, then the patient would need only be followed-up for a repeat 
CD4 test in six months’ time. Whereas, with a positive predictive value 
of only 84%, if the Pima™ result was less than 350 cells/μl, additional 
confirmatory laboratory CD4 testing would be required. In addition to 
this, it could be advocated that the Pima™ result be given as an “above” 
or “below” current ART eligibility threshold, rather than a numerical 
value. This would ensure that the Pima™ result was used in the correct 
context of assessing ART eligibility, rather than the potentially misleading 
situation of direct comparison with a prior or subsequent laboratory CD4 
result. This study did not evaluate the Pima™ CD4 analyser as a tool 
to monitor response to treatment. In this regard, greater emphasis is 
now being placed on the use of viral loads, rather than the CD4 count.26 
Further research is vital to evaluate performance in the field of this and 
other emerging POC tests. 
Importantly, the perception by healthcare workers and attending doctor 
involved in this study was that the immediate, tangible CD4 result at 
the time of the clinical visit significantly aided patient education, and 
understanding and motivation with respect to access to clinic care. 
However, our study was not designed to comment on the impact of 
subsequent ART uptake, or on the successful referral and ART initiation 
pattern. Positive impact from studies in Mozambique and South Africa 
was documented which showed that instantaneous CD4 results at 
the time of HIV testing improved ART initiation rates, and could have 
assisted with retention in care.27-29 It is worth noting that in current 
circumstances, even with POC CD4 testing, patients who qualify for ART 
will still be required to pay additional visits to the clinic for a review 
of other necessary test results, such as tuberculosis screening and 
renal function tests. For this reason, it may be worthwhile researching 
additional innovative methods that focus on behavioural interventions, 
such as SMS communications, which could potentially reduce time 
spent visiting the clinic.
Although the Pima™ CD4 analyser produces results relatively rapidly, it 
would still be regarded as a time-consuming procedure in the context 
of a busy paediatric clinic. Depending on the prevalence of HIV-infected 
mothers who miss their routine CD4 screening, the CD4 testing could 
become rate limiting in terms of how many patients could be seen. In 
such a case, it would be more practical to implement a nurse-driven 
service to ensure that maternal Pima™ CD4 testing is performed prior to 
the doctor’s consultation. In turn, many factors, such as excessive patient 
load, lack of adequately trained staff, and quality and stock control issues, 
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might negatively influence the feasibility of such a practice. The clinical 
setting is likely to influence whether or not the benefits of integrating 
this POC testing would outweigh implementation difficulties. The ideal 
would be to provide a “one-stop shop” in rural areas where patients are 
required to travel vast distances to visit the clinic. Mothers could have 
instant access to their CD4 results at the same time as attending their 
child’s appointment, negating the need for them to return on a separate 
occasion to obtain their CD4 results. Careful thought and planning 
around efficient patient flow could mitigate problems surrounding the 
time required to complete a POC CD4 test.
A technical limitation of the Pima™ device is that it does not provide 
values for a CD4 T-lymphocyte count percentage. Conventionally, this 
percentage value is used more in paediatric patients, because it varies 
less with age than the absolute count, and this restriction would have 
to be a consideration before the incorporation of POC systems into 
paediatric clinics. However, it is noted that in recent studies, more 
emphasis is being placed on the absolute CD4 cell count as a prognostic 
indicator of short-term disease progression in children.30,31
This study did not address the cost-effectiveness of the Pima™ POC 
system. Further controlled, cost-benefit field studies, preferably in the 
community in a primary or secondary setting, are needed to evaluate 
the Pima™ POC device, as well as other POC devices, in a comparison 
with current delivery methods. This would ensure the most efficient use 
of resources.  
Conclusion
Our study showed that the routine paediatric HIV care visit provides 
a valuable, additional intervention opportunity to identify a break in 
maternal HIV care. Point-of-care CD4 technology can meaningfully 
supplement screening for ART eligibility, particularly with reference to 
the exclusion of patients who are not eligible for ART. With good quality 
control of the POC deployment, the Pima™ CD4 could have a valid 
place as a low-cost, first-line screening tool, requiring a confirmatory 
laboratory test if found to be in the CD4 range in which treatment is 
indicated. The exact role that this early intervention would play, in terms 
of improving ART uptake, cost-effectiveness and best implementation 
of the POC systems in HIV care needs to be established with regard to 
relevant local circumstances.  
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